BioRestorative Therapies Announces Reverse Stock Split

BioRestorative will implement a 1-for-20 reverse split to consolidate shares and target continued Nasdaq Capital Market listing.

Rhea-AI Summary

BioRestorative Therapies (BRTX) approved a 1-for-20 reverse stock split of its common stock, with the change effective as of 4:30 p.m. Eastern Time on September 7, 2026. The stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market on September 8, 2026, under symbol BRTX and new CUSIP 090655705.

The split is intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement. Outstanding common shares will be reduced from 27,622,556 as of August 28, 2026, to approximately 1,381,128, and authorized shares will decrease proportionately from 1,500,000,000 to 75,000,000. Each twenty shares will convert into one share with unchanged par value, and ownership percentages are expected to remain the same except for fractional share rounding, where holders will receive one whole share rounded up.

Positive

• 1-for-20 reverse stock split reduces outstanding shares from 27,622,556 to approximately 1,381,128
• Authorized common shares cut from 1,500,000,000 to 75,000,000, aligning capital structure with the new share count
• Reverse split is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing
• Fractional shares will be rounded up so each affected holder receives one whole share of common stock

Negative

• Company must execute a reverse split to address Nasdaq’s $1.00 minimum bid price requirement for continued listing

News Explained

Beyond converting common shares, the reverse split will proportionally adjust outstanding options, warrants, other incentive awards, their exercise prices, and shares reserved under the 2021 plan.

Argus Sep 3 session 35 alerts

-28.76% close to close 285.3x rel. volume Open Argus

Details

Market move: BRTX -28.76% in the Sep 3 session. 1-for-20 reverse stock split

+3.8% Peak Tracked

-16.2% Trough Tracked

$4.42M Mkt Cap at Peak Alert

On Sep 3, the first trading day after this news, BRTX closed 28.76% below the previous close. Argus tracked a peak move of +3.8% during that session. Argus tracked a trough of -16.2% from its starting point during tracking. Our momentum scanner recorded 35 alerts for this stock that day. Relative volume reached 285.3x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 3 session.

Key Figures

Reverse split ratio: 1-for-20 Effective date: 4:30 P.M. Eastern Time on September 7, 2026 Adjusted trading date: September 8, 2026 +4 more

Reverse split ratio

1-for-20

Reverse Stock Split

Effective date

4:30 P.M. Eastern Time on September 7, 2026

Certificate of change effectiveness

Adjusted trading date

September 8, 2026

Reverse split-adjusted Nasdaq trading

New CUSIP

090655705

Reverse split-adjusted trading

Minimum bid requirement

$1.00

Nasdaq Listing Rule 5550(a)(2)

Issued shares

27,622,556 to approximately 1,381,128 shares

As of August 28, 2026 and after implementation

Authorized shares

1,500,000,000 to 75,000,000 shares

Proportional reduction under Nevada law

Historical Context

5 past events · Latest: Jun 25

5 events

1. Jun 25

   Clinical manufacturing

   24h Move

   -0.8%

   Completed BRTX-100 Phase 2 clinical supply manufacturing

2. Jun 18

   Leadership appointment

   24h Move

   +2.5%

   Appointed healthcare executive to lead Biocosmeceuticals expansion

3. May 27

   Stake acquisition

   24h Move

   +73.3%

   Investor acquired a 4.9% stake through open-market purchases

4. May 26

   Clinical trial update

   24h Move

   +20.1%

   Completed Phase 2 dosing in a 99-patient BRTX-100 trial

5. May 13

   Preclinical data

   24h Move

   -5.8%

   Presented preclinical exosome functionality data at ISCT 2026

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

reverse stock split, cusip number

2 terms

reverse stock split financial

"approved a 1-for-20 reverse stock split of the Company's common stock"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

cusip number technical

"under a new CUSIP number, 090655705"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

Upon implementation of the Reverse Stock Split, every twenty shares of the Company’s issued and outstanding Common Stock will automatically convert into one share of Common Stock without any change to the par value of $0.0001 per share, and the number of shares of Common Stock issued and outstanding will be reduced from 27,622,556 shares as of August 28, 2026, to approximately 1,381,128 shares. In accordance with Nevada law, the number of authorized shares of Common Stock will be reduced proportionately from 1,500,000,000 shares to 75,000,000 shares. Following the Reverse Stock Split, the ownership percentage of each stockholder will remain unchanged, other than as a result of the treatment of fractional shares. Proportional adjustments will be made to the number of shares of Common Stock issuable upon exercise of the Company’s outstanding stock options and warrants, and other incentive awards, as well as the applicable exercise prices, and to the number of shares reserved for issuance under the Company’s 2021 Stock Incentive Plan.

No fractional shares of Common Stock will be issued in connection with the Reverse Stock Split. Instead, each holder of record who would otherwise be entitled to receive a fractional share will receive one whole share of Common Stock, rounded up to the nearest whole share. Stockholders holding shares in street name through a bank, broker, or other nominee will have their positions adjusted in accordance with the procedures of such bank, broker, or nominee.

Information for Stockholders

TranShare Corporation, the Company’s transfer agent, will send instructions to stockholders of record who hold stock certificates regarding the exchange of certificates for Common Stock. Stockholders who hold their shares of Common Stock in book-entry form or in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares of Common Stock following the Reverse Stock Split.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs relate to the treatment of disc/spine disease (our lead cell therapy candidate, BRTX-100, is currently in a Phase 2 clinical trial for the treatment of chronic lumbar disc disease) and metabolic disorders (our ThermoStem® Program). We have also developed a commercial biocosmeceutical platform through which we formulate, manufacture and sell cell-based biologic aesthetic products.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to qualify for the protection of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “targets,” “will,” “would,” and similar expressions, and the negatives of those terms. Forward-looking statements in this press release include, among others, statements regarding the timing and effectiveness of the Reverse Stock Split and the anticipated market-effective and first-trading dates; the anticipated post-split trading price of the Common Stock and the ability of the Reverse Stock Split to result in a sustained increase in the price of the Common Stock to a level at or above $1.00 per share; the expected number of shares of Common Stock outstanding following the Reverse Stock Split and the effect of the treatment of fractional shares; the proportional adjustment of the Company’s outstanding stock options, warrants, and other equity awards; and the Company’s ability to regain and maintain compliance with all applicable continued listing standards of The Nasdaq Capital Market.

These forward-looking statements are based on the Company’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the Reverse Stock Split does not result in a sustained increase in the price of the Common Stock, or that the price of the Common Stock subsequently declines below $1.00 per share, which could result in non-compliance with Nasdaq continued listing standards or delisting proceedings; the risk that the Reverse Stock Split causes the Company to fall out of compliance with another Nasdaq listing requirement, including the requirement to maintain a minimum number of publicly held shares; restrictions under Nasdaq rules that limit the Company’s ability to effect additional reverse stock splits within a one-year period to regain compliance with the minimum bid price requirement; the volatility of the market price and trading volume of the Common Stock; and general business, economic, and market conditions, as well as the other risks and uncertainties described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Copies of these filings are available at www.sec.gov.

Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by applicable law. You should not place undue reliance on these forward-looking statements.

Investor Contact:

Rory Rumore

Investor Relations

investors@biorestorative.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse stock split did BioRestorative Therapies (BRTX) announce?

BioRestorative Therapies announced a 1-for-20 reverse stock split of its common stock. Every twenty issued and outstanding shares will automatically convert into one share, with no change to the par value of $0.0001 per share.

When does the BRTX reverse stock split become effective and when will split-adjusted trading begin?

The reverse stock split is expected to become effective at 4:30 p.m. Eastern Time on September 7, 2026. BioRestorative’s common stock will begin trading on a reverse split-adjusted basis on September 8, 2026 on The Nasdaq Capital Market.

How will BioRestorative Therapies’ (BRTX) share count change after the reverse split?

After the 1-for-20 reverse split, outstanding common shares will be reduced from 27,622,556 as of August 28, 2026, to approximately 1,381,128 shares. Authorized common shares will also decrease proportionately from 1,500,000,000 to 75,000,000.

Why is BioRestorative Therapies (BRTX) implementing a reverse stock split?

The company is effecting the reverse stock split with the intention of regaining compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2).

What happens to fractional shares in the BioRestorative Therapies (BRTX) reverse split?

No fractional shares will be issued. Instead, each holder of record who would otherwise receive a fractional share will receive one whole share of common stock, rounded up to the nearest whole share after the reverse split.

Will the BioRestorative Therapies (BRTX) reverse split change shareholder ownership percentages?

Following the reverse stock split, the ownership percentage of each stockholder is expected to remain unchanged, other than minor effects from the treatment of fractional shares, which are rounded up to a full share for eligible holders.

Do BRTX shareholders need to take any action for the reverse stock split?

Stockholders holding shares in book-entry, brokerage, or street name are not required to take action. TranShare Corporation will send instructions to registered holders of certificates regarding exchanging them for post-split common stock.